期刊
LEUKEMIA RESEARCH
卷 34, 期 5, 页码 610-614出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2009.08.010
关键词
Elderly acute myeloid leukemia; Low-dose chemotherapy; Cytarabine; Aclarubicin; Granulocyte colony-stimulating factor; CAG
资金
- Japanese Ministry of Education, Culture, Sport, Science and Technology
- Japanese Ministry of Health, Labor and Welfare
We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia. Patients aged between 60 and 70 years who were not eligible for standard chemotherapy protocols and patients aged over 70 years were all registered. Thirty-three of 68 patients (49%) achieved remission. Median disease-free survival was 10 months and overall survival was nine months. Performance status after chemotherapy in patients who achieved remission was generally favorable. The present study demonstrates that CAG therapy is efficacious and well tolerated in the majority of elderly patients. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据